Frequent p16ink4a inactivation is an early and frequent event of intraductal papillary neoplasm of the liver arising in hepatolithiasis

Human Pathology

Volumn 35, Issue 12, 2004, Pages 1505-1514

  Ishikawa, Akira ^a,b   Sasaki, Motoko ^a   Sato, Yasunori ^a   Ohira, Shusaku ^a,b   Chen, Miin Fu ^c   Huang, Shiu Feng ^c   Oda, Koji ^b   Nimura, Yuji ^a,b   Nakanuma, Yasuni ^a,b  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

biliary epithelial dysplasia; CDK; cell cycle regulator; chronic cholangitis; cyclin dependent kinase; ICC; intraductal papillary neoplasm of the liver; intrahepatic cholangiocarcinoma; intrahepatic choloangiocarcinoma; IPNL; laser capture microdissection; LI

Indexed keywords

CYCLIN D1; PROTEIN MDM2; PROTEIN P16; PROTEIN P21; PROTEIN P23; PROTEIN PRB; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; DNA; PROTEIN P16INK4A; TUMOR MARKER;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; BILE DUCT CANCER; BILE DUCT CARCINOMA; BILE DUCT STONE; CANCER INVASION; CARCINOMA IN SITU; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DYSPLASIA; FEMALE; GENE INACTIVATION; HUMAN; HUMAN TISSUE; INTRAHEPATIC BILE DUCT; LIVER RESECTION; LIVER TUMOR; MALE; METHYLATION; PAPILLOMA; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN EXPRESSION; BILE DUCT TUMOR; CHOLELITHIASIS; DNA METHYLATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROTEIN MICROARRAY; TUMOR SUPPRESSOR GENE;

ADENOMA, BILE DUCT; ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA IN SITU; CELL CYCLE PROTEINS; CHOLELITHIASIS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, P16; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROTEIN ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 10944237188     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2004.08.014     Document Type: Article

References (34)

1. Nakanuma Y., Sripa B., Vatanasapt V., et al. Intrahepatic cholangiocarcinoma. Hamilton S.R., Aaltonen L.A. World Health Organization Classification of Tumours, Pathology and Genetics Tumours of the Digestive System. 2000;173-180 IARC Press, Lyon, France
2. Portmann B.C., Nakanuma Y. Disease of the bile ducts. MacSween R.N.M., Burt A.D., Portmann B.C.,, et al. Pathology of the Liver. (ed 4):2002;436-506 Churchill Livingstone, London
3. Nakanuma Y., Yamaguchi K., Ohta G., et al. Pathological features of hepatolithiasis in Japan. Hum Pathol. 19:1988;1181-1186
4. Nakanuma Y., Terada T., Tanaka Y., et al. Are hepatolithiasis and cholangiocarcinoma aetiologically related? A morphological study of 12 cases of hepatolithiasis associated with cholangiocarcinoma. Virchows Arch A. 406:1985;45-58
5. Nakanuma Y., Sasaki M., Ishikawa A., et al. Biliary papillary neoplasm of the liver. Histol Histopathol. 17:2002;851-861
6. Terada T., Nakanuma Y., Ohta T., et al. Histological features and interphase nucleolar organizer regions in hyperplastic, dysplastic and neoplastic epithelium of intrahepatic bile ducts in hepatolithiasis. Histopathology. 21:1992;233-240
7. Chen T.C., Nakanuma Y., Zen Y., et al. Intraductal papillary neoplasia of the liver associated with hepatolithiasis. Hepatology. 34:2001;651-658
8. Caffo O., Doglioni C., Veronese S., et al. Prognostic value of p21(WAF1) and p53 expression in breast carcinoma An immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res. 2:1996;1591-1599
9. Hsieh C.J., Klump B., Holzmann K., et al. Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. Cancer Res. 58:1998;3942-3945
10. Klump B., Hsieh C.J., Holzmann K., et al. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. Gastroenterology. 115:1998;1381-1386
11. Tannapfel A., Benicke M., Katalinic A., et al. Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut. 47:2000;721-727
12. Klump B., Hsieh C.J., Dette S., et al. Promoter methylation of INK4a/ARF as detected in bile-significance for the differential diagnosis in biliary disease. Clin Cancer Res. 9:2003;1773-1778
13. Barrett M.T., Sanchez C.A., Galipeau P.C., et al. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene. 13:1996;1867-1873
14. Caca K., Feisthammel J., Klee K., et al. Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines. Int J Cancer. 97:2002;481-488
15. Yoshida S., Todoroki T., Ichikawa Y., et al. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. Cancer Res. 55:1995;2756-2760
16. Lee J.-H., Furth E.E., Wu T.T., et al. Intraductal papillary neoplasms of the biliary tree Molecular and immunohistochemical analysis. Mod Pathol. 14:2001;199A
17. Ohita H., Yamaguchi Y., Yamakawa O., et al. Biliary papillomatosis with the point mutation of K-ras gene arising in congenital choledochal cyst. Gastroenterology. 105:1993;1209-1212
18. Abraham S.C., Lee J.H., Boitnott J.K., et al. Microsatellite instability in intraductal papillary neoplasms of the biliary tract. Mod Pathol. 15:2002;1309-1317
19. Nakanuma Y., Hoso M., Sanzen T., et al. Microstructure and development of the normal and pathologic biliary tract in humans, including blood supply. Microsc Res Tech. 38:1997;552-570
20. Kang Y.K., Kim W.H., Jang J.J. Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. Hum Pathol. 33:2002;877-883
21. Palmisano W.A., Divine K.K., Saccomanno G., et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60:2000;5954-5958
22. Fukushima N., Sato N., Ueki T., et al. Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am J Pathol. 160:2002;1573-1581
23. Taniai M., Higuchi H., Burgart L.J., et al. p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology. 123:2002;1090-1098
24. Tannapfel A., Sommerer F., Benicke M., et al. Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma. J Pathol. 197:2002;624-631
25. Jang T.J., Kim D.I., Shin Y.M., et al. p16(INK4a) promoter hypermethylation of non-tumorous tissue adjacent to gastric cancer is correlated with glandular atrophy and chronic inflammation. Int J Cancer. 93:2001;629-634
26. Hara E., Smith R., Parry D., et al. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol. 16:1996;859-867
27. Nishida N., Fukuda Y., Komeda T., et al. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res. 54:1994;3107-3110
28. Ito Y., Takeda T., Sasaki Y., et al. Expression and clinical significance of the G1-S modulators in intrahepatic cholangiocellular carcinoma. Oncology. 60:2001;242-251
29. Yamamoto Y., Gaynor R.B. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Invest. 107:2001;135-142
30. Hinz M., Krappmann D., Eichten A., et al. NF-κB function in growth control Regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol. 19:1999;2690-2698
31. Furubo S., Harada K., Shimonishi T., et al. Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma. Histopathology. 35:1999;230-240
32. Iggo R., Gatter K., Bartek J., et al. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet. 335:1990;675-679
33. Blagosklonny M.V. Loss of function and p53 protein stabilization. Oncogene. 15:1997;1889-1893
34. Momoi H., Itoh T., Nozaki Y., et al. Microsatellite instability and alternative genetic pathway in intrahepatic cholangiocarcinoma. J Hepatol. 35:2001;235-244